MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
1.240
+0.010
+0.81%
Closed 16:00 04/24 EDT
OPEN
1.240
PREV CLOSE
1.240
HIGH
1.290
LOW
1.215
VOLUME
129.68K
TURNOVER
0
52 WEEK HIGH
3.110
52 WEEK LOW
0.9451
MARKET CAP
111.70M
P/E (TTM)
-0.5871
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IMUX last week (0415-0419)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)
TipRanks · 04/16 06:50
Weekly Report: what happened at IMUX last week (0408-0412)?
Weekly Report · 04/15 09:18
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Piper Sandler published the top 10 stocks with upwards and downwards daily percentage change as of Thursday. The S&P 500 (SP500) is vulnerable to a possible 5-10% pullback in upcoming weeks or months, analysts say. High-interest rates, inflation, and mediocre breadth are making the market vulnerable to pullback, Piper Sandler says.
Seeking Alpha · 04/12 15:34
Immunic, Inc. (NASDAQ:IMUX): When Will It Breakeven?
Immunicic, Inc. Develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. The biotechnology company posted a loss of US$94m in its most recent financial year. The company is projected to become profitable around 2 years from now. An average annual growth rate of 58% is expected for Immunic to reach breakeven.
Simply Wall St · 04/11 11:10
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
TipRanks · 04/10 11:20
Weekly Report: what happened at IMUX last week (0401-0405)?
Weekly Report · 04/08 09:19
Brookline Capital starts Immunic at buy, cites MS drug candidate
Healthcare Brookline Capital starts Immunic at buy, cites MS drug candidate IMU-838. Investment firm cites potential of the company’s multiple sclerosis drug candidate. The firm set its price target for the stock at $10, citing the potential of Immunic.
Seeking Alpha · 04/05 17:00
More
About IMUX
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.